Recent Advances in CD8 T Cell-based Immune Therapies for HIV Cure

Overview

Journal Heliyon

Specialty Social Sciences

Date 2023 Jul 13

PMID 37441388

Authors

Valentina Restrepo Arenas

Maria T Rugeles

Federico Perdomo-Celis

Natalia Taborda

Affiliations

Soon will be listed here.

Abstract

Achieving a cure for HIV infection is a global priority. There is substantial evidence supporting a central role for CD8 T cells in the natural control of HIV, suggesting the rationale that these cells may be exploited to achieve remission or cure of this infection. In this work, we review the major challenges for achieving an HIV cure, the models of HIV remission, and the mechanisms of HIV control mediated by CD8 T cells. In addition, we discuss strategies based on this cell population that could be used in the search for an HIV cure. Finally, we analyze the current challenges and perspectives to translate this basic knowledge toward scalable HIV cure strategies.

Citing Articles

Interventions during Early Infection: Opening a Window for an HIV Cure?.

Hiner C, Mueller A, Su H, Goldstein H Viruses. 2024; 16(10).

PMID: 39459922 PMC: 11512236. DOI: 10.3390/v16101588.

Bridging the gap with multispecific immune cell engagers in cancer and infectious diseases.

Rolin C, Zimmer J, Seguin-Devaux C Cell Mol Immunol. 2024; 21(7):643-661.

PMID: 38789528 PMC: 11214628. DOI: 10.1038/s41423-024-01176-4.

References

Garcia F, Climent N, Assoumou L, Gil C, Gonzalez N, Alcami J . A therapeutic dendritic cell-based vaccine for HIV-1 infection. J Infect Dis. 2011; 203(4):473-8. PMC: 3071229. DOI: 10.1093/infdis/jiq077. View

Blazek D, Teque F, Mackewicz C, Peterlin M, Levy J . The CD8+ cell non-cytotoxic antiviral response affects RNA polymerase II-mediated human immunodeficiency virus transcription in infected CD4+ cells. J Gen Virol. 2015; 97(1):220-224. PMC: 4772706. DOI: 10.1099/jgv.0.000326. View

Kagi D, Vignaux F, Ledermann B, Burki K, Depraetere V, Nagata S . Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science. 1994; 265(5171):528-30. DOI: 10.1126/science.7518614. View

Haran K, Hajduczki A, Pampusch M, Mwakalundwa G, Vargas-Inchaustegui D, Rakasz E . Simian Immunodeficiency Virus (SIV)-Specific Chimeric Antigen Receptor-T Cells Engineered to Target B Cell Follicles and Suppress SIV Replication. Front Immunol. 2018; 9:492. PMC: 5869724. DOI: 10.3389/fimmu.2018.00492. View

. Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015. Lancet HIV. 2016; 3(8):e361-e387. PMC: 5056319. DOI: 10.1016/S2352-3018(16)30087-X. View

Guo Y, Xie Y, Gao M, Zhao Y, Franco F, Wenes M . Metabolic reprogramming of terminally exhausted CD8 T cells by IL-10 enhances anti-tumor immunity. Nat Immunol. 2021; 22(6):746-756. PMC: 7610876. DOI: 10.1038/s41590-021-00940-2. View

Joseph A, Zheng J, Follenzi A, Dilorenzo T, Sango K, Hyman J . Lentiviral vectors encoding human immunodeficiency virus type 1 (HIV-1)-specific T-cell receptor genes efficiently convert peripheral blood CD8 T lymphocytes into cytotoxic T lymphocytes with potent in vitro and in vivo HIV-1-specific inhibitory.... J Virol. 2008; 82(6):3078-89. PMC: 2258988. DOI: 10.1128/JVI.01812-07. View

Mansky L, Temin H . Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol. 1995; 69(8):5087-94. PMC: 189326. DOI: 10.1128/JVI.69.8.5087-5094.1995. View

Chiu C, Chang J, Dantanarayana A, Solomon A, Evans V, Pascoe R . Combination Immune Checkpoint Blockade Enhances IL-2 and CD107a Production from HIV-Specific T Cells Ex Vivo in People Living with HIV on Antiretroviral Therapy. J Immunol. 2021; 208(1):54-62. PMC: 8702486. DOI: 10.4049/jimmunol.2100367. View

10.

Oh S, Berzofsky J, Burke D, Waldmann T, Perera L . Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity. Proc Natl Acad Sci U S A. 2003; 100(6):3392-7. PMC: 152303. DOI: 10.1073/pnas.0630592100. View

11.

Shiver J, Fu T, Chen L, Casimiro D, Davies M, Evans R . Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 2002; 415(6869):331-5. DOI: 10.1038/415331a. View

12.

Milburn J, Jones R, Levy J . Renal effects of novel antiretroviral drugs. Nephrol Dial Transplant. 2016; 32(3):434-439. PMC: 5837523. DOI: 10.1093/ndt/gfw064. View

13.

Molinos-Albert L, Lorin V, Monceaux V, Orr S, Essat A, Dufloo J . Transient viral exposure drives functionally-coordinated humoral immune responses in HIV-1 post-treatment controllers. Nat Commun. 2022; 13(1):1944. PMC: 9001681. DOI: 10.1038/s41467-022-29511-1. View

14.

Ruff C, Ray S, Kwon P, Zinn R, Pendleton A, Hutton N . Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure. J Virol. 2002; 76(18):9481-92. PMC: 136462. DOI: 10.1128/jvi.76.18.9481-9492.2002. View

15.

Cullell-Young M, Barrachina M, Lopez-Lopez C, GONALONS E, Lloberas J, Soler C . From transcription to cell surface expression, the induction of MHC class II I-A alpha by interferon-gamma in macrophages is regulated at different levels. Immunogenetics. 2001; 53(2):136-44. DOI: 10.1007/s002510100312. View

16.

Sharaf R, Lee G, Sun X, Etemad B, Aboukhater L, Hu Z . HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers. J Clin Invest. 2018; 128(9):4074-4085. PMC: 6118642. DOI: 10.1172/JCI120549. View

17.

McLane L, Abdel-Hakeem M, Wherry E . CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer. Annu Rev Immunol. 2019; 37:457-495. DOI: 10.1146/annurev-immunol-041015-055318. View

18.

Hansen S, Sacha J, Hughes C, Ford J, Burwitz B, Scholz I . Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms. Science. 2013; 340(6135):1237874. PMC: 3816976. DOI: 10.1126/science.1237874. View

19.

Borrow P, Lewicki H, Hahn B, Shaw G, Oldstone M . Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol. 1994; 68(9):6103-10. PMC: 237022. DOI: 10.1128/JVI.68.9.6103-6110.1994. View

20.

Bertagnolli L, Varriale J, Sweet S, Brockhurst J, Simonetti F, White J . Autologous IgG antibodies block outgrowth of a substantial but variable fraction of viruses in the latent reservoir for HIV-1. Proc Natl Acad Sci U S A. 2020; 117(50):32066-32077. PMC: 7749285. DOI: 10.1073/pnas.2020617117. View